Affordable Access

deepdyve-link
Publisher Website

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.

Authors
  • Fazio, Nicola1
  • Granberg, Dan2
  • Grossman, Ashley3
  • Saletan, Stephen4
  • Klimovsky, Judith4
  • Panneerselvam, Ashok4
  • Wolin, Edward M5
  • 1 European Institute of Oncology, Milan, Italy. Electronic address: [email protected] , (Italy)
  • 2 Departments of Medical Sciences and Endocrine Oncology, Uppsala University, Uppsala, Sweden. , (Sweden)
  • 3 Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital University of Oxford, Oxford, England.
  • 4 Novartis Pharmaceuticals Corp, Florham Park, NJ.
  • 5 Cedars-Sinai Medical Center, Los Angeles, CA.
Type
Published Article
Journal
CHEST Journal
Publisher
Elsevier
Publication Date
April 2013
Volume
143
Issue
4
Pages
955–962
Identifiers
DOI: 10.1378/chest.12-1108
PMID: 23187897
Source
Medline
License
Unknown

Abstract

ClinicalTrials.gov; No.: NCT00412061

Report this publication

Statistics

Seen <100 times